Over-The-Counter (OTC) Analgesics Market Size To Reach USD 40,930 Million By 2032
| Regulatory Scrutiny | Increase misuse may attract regulatory attension, authority will impose stricter regulation, which can affect availability and marketing of OTC Analgesics. |
| Product Restriction | Authority might impose restriction on OTC Analgesics or their components if abuse become a significant issue. |
| Market Perception | Overuse and misuse of OTC drug turns the reputation, leading consumer to question their safety and efficacy. This negative impact will decline the sale of OTC Analgesics. |
| Increased Oversight Cost | Manufacturer and sellers may face increased cost associated with implementing measures to prevent abuse, such as enhance packaging, monitoring and education campaigns. |
Management of Chronic Pain by using Advancing OTC Analgesic:
The CDC estimates that 51 million Americans suffered from prolonged pain in 2021, making the condition's effective treatment a public health necessity. Opioids are still frequently prescribed, considering that many analgesics are known to be effective in treating pain; 22% of patients with chronic pain use a prescription for opioids. Nonsteroidal anti-inflammatory medications (NSAIDs) and acetaminophen are two more commonly used oral therapies for chronic pain.
About 20% of people in the developed world suffer from chronic pain, a complex disorder that has psychological as well as physical symptoms. Manage by treating mild to moderate pain, nonopioid analgesics are typically used first. It makes sense to add a mood stabilizer with analgesic properties if this is insufficient and there is a possibility of sleep deprivation. A trial using one of the gabapentinoids would be suitable if fibromyalgia or neuropathic pain are present. It may be necessary to add an opioid analgesic if these measures prove insufficient. An early long-term opioid trial would be started for mild to severe pain. Topicals and skeletal muscle relaxants may be suitable in their own right.
For Instance,
- The American Heart Association recommends patients with coronary artery disease take acetaminophen, nonacetylated salicylates, and even short-term opioids rather than NSAIDs, especially COX-2 agents. Like NSAIDs, acetaminophen has analgesic and antipyretic properties, but it does not specifically reduce inflammation. Although acetaminophen has a slightly worse analgesic profile than NSAIDs, its better safety record and lower cost make it a reasonable first-line option. There is growing evidence that patients with chronic pain may benefit from the use of controlled-release opioid analgesics. In patients with nociceptive and neuropathic pain, opioids were found to be more effective than placebo for both pain and functional outcomes in a recent review of 41 randomized controlled studies involving 6,019 patients. In 2020, The U.S. Food and Drug Administration launched Analgesic Clinical Trial Innovations, Opportunities, and Networks (ACTION), a public-private partnership intended to facilitate the discovery and development of analgesics with improved efficacy, safety, and tolerability for acute and chronic pain.
Various factors such as patient characteristics, clinical trial methodology and methods, outcome measures, data analysis approaches, and statistical power may contribute to the challenges encountered in proving the superiority of effective analgesic treatments over placebo. A evidence-based strategy for the design of analgesic research studies may be established by identifying particular trial characteristics linked to assay sensitivity in the available data.
Investing in research on the appropriate areas and raising awareness about chronic pain can help develop more precise analgesics and shorten the time it takes for patients to receive a diagnosis. Research projects that incorporate patient involvement and gain a deeper understanding of diseases have a significantly higher chance of success. The following guidelines are essential for the success of analgesic innovation.
Browse More Insights of Towards Healthcare:
- The global central lab market size is projected to reach an estimated USD 5.4 billion by 2032 to grow from USD 3.1 billion in 2022 at a CAGR of 5.71% between 2023-2032.
The global biosimilar market size is estimated to reach around USD 1,26,019.67 million by 2032 and was estimated to grow from USD 25,125.36 million in 2022 at 17.6% of CAGR between 2023 and 2032.
The global chatbots for mental health and therapy market size was valued at USD 0.99 billion in 2022 expanding at a CAGR of 21.3% and is estimated to surpass around USD 6.51 billion by 2032.
The global genomics market size surpassed USD 28.9 billion in 2022 and is estimated to reach around USD 127.16 billion by 2032, expanding at a CAGR of 16.1% from 2023 to 2032.
The global artificial intelligence in life sciences industry size was estimated at USD 1.56 billion in 2022 and it is expected to reach around USD 9.80 billion by 2032 with a registered CAGR of 20.21% from 2023 to 2032.
Type of Drug Segment Drives Growth in Over-the-Counter Analgesic Market:
- Acetaminophen is primarily given as 1st line treatment of Joint Pain. It is used as a pain reliever and fever reducer. it relieves mild-to-moderate pain from conditions such as headache, muscle pain, and toothache; acetaminophen has minimal anti-inflammatory effects. Those patients are not able to tolerate NSAIDs in that case, acetaminophen is given. Market growth is rising due to safety, efficacy, availability, and consumer familiarity, which helps to grow the OTC Analgesics Market. Non-steroidal anti-inflammatory drugs are commonly given in chronic pain to reduce inflammation and lower fever. The common indication includes it treats Arthritis, Muskoskeletan injuries and migraines. In the OTC Analgesic Market, NSAIDs contribute to growth by offering consumers accessible pain relief options without a prescription. Their effectiveness in managing various types of pain has led to widespread use, Contributing to the expansion of the OTC Analgesic Market. Salicylate is the Derivative of Acetyl salicylic Acid it includes Aspirin. They have anti-inflammatory, analgesic, and antipyretic properties. In the OTC Analgesics Market, Salicylates contribute to growth by being a key component in many pain relief conditions. Aspirin is a widely used and available OTC drug, contributing to the market's expansion due to its versatility in addressing various conditions.
Geographical Landscape:
For several important reasons, North America dominates the over-the-counter (OTC) analgesics market. Initially, the demand for over-the-counter analgesics is driven by the region's well-established healthcare infrastructure and high consumer health awareness. The ageing population and the frequency of chronic pain conditions also influence sustained usage. Strong pharmaceutical laws protect consumers by guaranteeing product safety and quality. Manufacturers engage in broad advertising and marketing campaigns to encourage consumption further. Lastly, North America's stronghold in the OTC analgesics market is further cemented by the presence of well-known pharmaceutical manufacturers and the broad availability of OTC products in retail stores.
Over-the-counter medications in the U.S. are the most frequently used, In 2020, According to the National Health and Institute, over 80 classes of over-the-counter medications, totalling up to 1,000,000 marketed products, are available in the United States. OTC medications are thought to save the US economy $102 billion annually, of which $25 billion is attributed to their use and $77 billion to avoid needless hospital stays. As a result, the demand for OTC analgesics is expected to increase in the US.
According to the US FDA, OTC drugs should fulfil the following criteria:
- Good Benefit-Risk Ratio Minimal Abuse and Misuse Potential Consumer Awareness of its Use, and Sufficient Labelling
The status of EU member states, the European Medicines Agency (EMA) has divided pharmaceuticals into two groups: prescription drugs and over-the-counter drugs. In the UK and Germany, nonprescription medications are separated into pharmacy and general sales categories. Pharmacy medications are available without a prescription, but they should only be distributed under the surveillance of a licensed pharmacist because they cannot be chosen on your own. Germany makes up the largest portion of Europe's OTC market.
The three main drivers of growth in the region are China, Japan, and India. In terms of over-the-counter drug sales, the Asia Pacific market is one of the most rapidly expanding worldwide. The share is predicted to rise significantly throughout the forecast period. The growing older population and better healthcare facilities are predicted to drive regional market expansion. Additionally, as chronic diseases become more common, pharmaceutical companies are more likely to switch from prescriptions to over-the-counter (OTC) drugs. This trend is primarily responsible for the market growth in this region.
Competitive Landscape:
Several multinational pharmaceutical companies, including Bayer AG, Boehringer Ingelheim International GmbH, Johnson & Johnson, Haleon PLC, Novartis AG, Dr Reddy's Laboratories Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc., are major players in the competitive landscape of the over-the-counter analgesic market. A big part is also played by generic and branded labels, which provide affordable substitutes. Market positioning is influenced by regulation components, marketing tactics, and product innovations, particularly on analgesic formulations like salicylate, acetaminophen, and NSAIDs. Global market trends, consumer preferences, and distribution channels influence OTC analgesic market competitiveness.
Companies are attempting to take a few critical actions to obtain an edge in competition. They're investing more in research and development, creating creative and original solutions, bringing them to market, collaborating with other businesses, and providing distinctive amenities. These tactics aid their mutual establishment and enable them to outperform their rivals.
Recent Development:
- In January 2022, CV Sciences Inc. announced the launch of a new class of OTC Analgesics. The +CBD Analgesics is equipped with hemp-derived CBD aimed at soothing minor pains and consist of four unique product to choose from. In 2021, the FDA approved Topical Diclofenac as an NSAID analgesic for treating Knee osteoarthritis. In March 2021 , Hisamitsu America announced FDA approval for the over-the-counter use of Solanpas Arthritis Analgesic Gel, the most prescribed analgesic gel clinically proven for joint pain.
Market Players:
- Bayer AG Boehringer Ingelheim International Gmb Johnson & Johnson Haleon PLC Novartis AG Dr. Reddy's Laboratories Ltd Sanofi SA Sun Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd Viatris Inc.
Market Segments:
By Type of Drug
- Acetaminophen Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Salicylates Other Analgesics
By Route of Administration
- Oral Topical Others
By Distribution Channel
- Hospital Pharmacies Retail Pharmacies Online Pharmacies Other Distribution Channels
By Geography
- North America
- U.S. Canada
- U.K. Germany France Rest of Europe
- China India Japan South Korea Rest of Asia Pacific
- Brazil Rest of Latin America
- Saudi Arabia UAE South Africa Rest of the Middle East & Africa
You can place an order or ask any questions, please feel free to contact us at ...
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Web:
Browse our Brand-New Journal@
Browse our Consulting Website@
For Latest Update Follow Us:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment